Skip to main content

Aravive, Inc. (ARAV)

NASDAQ: ARAV · Delayed Price · USD
2.95
0.16 (5.73%)
At close: Dec 8, 2021 4:00 PM
2.99
0.04 (1.36%)
After-hours:Dec 8, 2021 7:41 PM EST
Market Cap61.87M
Revenue (ttm)12.14M
Net Income (ttm)-30.24M
Shares Out20.97M
EPS (ttm)-1.68
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume96,941
Open2.85
Previous Close2.79
Day's Range2.76 - 2.98
52-Week Range2.41 - 9.95
Beta3.08
AnalystsStrong Buy
Price Target22.00 (+645.8%)
Earnings DateNov 3, 2021

About ARAV

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to blo...

IndustryBiotechnology
IPO DateMar 21, 2014
CEOGail McIntyre
Employees17
Stock ExchangeNASDAQ
Ticker SymbolARAV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Aravive stock is "Strong Buy." The 12-month stock price forecast is 22.00, which is an increase of 645.76% from the latest price.

Price Target
$22.00
(645.76% upside)
Analyst Consensus: Strong Buy

News

Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference

HOUSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today annou...

3 weeks ago - GlobeNewsWire

Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with ...

3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline Batiraxcept has been generally well-tolerated with no dose-limiting toxicities Aravive ...

4 weeks ago - GlobeNewsWire

Aravive (ARAV) Reports Q3 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of -26.19% and 2.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

HOUSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today annou...

1 month ago - GlobeNewsWire

Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference

HOUSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Ga...

2 months ago - GlobeNewsWire

Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference

HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Ga...

3 months ago - GlobeNewsWire

Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenoca...

Trial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel

3 months ago - GlobeNewsWire

Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

HOUSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced recent c...

4 months ago - GlobeNewsWire

Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference

HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gai...

4 months ago - GlobeNewsWire

Aravive Achieves Second Development Milestone from 3D Medicines

Milestone is Based on Approval of 3D Medicines' IND in China to Participate in Aravive's AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer Milestone is Based on Approval of 3...

4 months ago - GlobeNewsWire

Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference

HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gai...

5 months ago - GlobeNewsWire

Aravive (ARAV) Reports Q1 Loss, Lags Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of 2.22% and -54.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Re...

Addresses High Unmet Medical Need for Women with Advanced Ovarian Cancer

7 months ago - GlobeNewsWire

Aravive to Present Phase 1b Data Evaluating AVB-500 in Platinum Resistant Ovarian Cancer at 2021 Society of Gynecolog...

HOUSTON, March 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq:ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that updated data from its Phase 1b tri...

8 months ago - GlobeNewsWire

Aravive Announces $21.0 Million Registered Direct Offering with Eshelman Ventures, LLC Priced At-The-Market

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a securities p...

9 months ago - GlobeNewsWire

Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference

HOUSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present at the H.C. Wa...

11 months ago - GlobeNewsWire

Aravive Announces Board Member Transition to Advisory Role

HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will be steppin...

11 months ago - GlobeNewsWire

Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020

HOUSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will host a virtual Ovarian...

1 year ago - GlobeNewsWire

Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

HOUSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced recent corporate updates and financial ...

1 year ago - GlobeNewsWire

Aravive Appoints Michael W. Rogers to Board of Directors

Strengthens Advisory Team with Industry Veteran as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer (PROC) Strengthens Advisory Team with Industry Veteran as Company Advances AVB-500 in Pla...

1 year ago - GlobeNewsWire

Aravive Appoints Reshma Rangwala, M.D., Ph.D., as Chief Medical Officer

HOUSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the appointment of industry veteran ...

1 year ago - GlobeNewsWire

Aravive to Participate in Upcoming Virtual Investor Conferences in September

HOUSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and co...

1 year ago - GlobeNewsWire

Aravive Strengthens Leadership Team with Appointment of Key Industry Veterans

Expands Clinical Development and Oncology Expertise as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer Expands Clinical Development and Oncology Expertise as Company Advances AVB-500 in Pl...

1 year ago - GlobeNewsWire

Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates

HOUSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced recent corporate updates and financia...

1 year ago - GlobeNewsWire

Aravive to Participate in Upcoming Virtual Investor Conferences in August

HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and con...

1 year ago - GlobeNewsWire